GSK Singapore: Overview of GlaxoSmithKline’s Singapore Operations

Welcome to the world of GSK Singapore! As a healthcare company with a global presence, GSK has been operating in Singapore since 1959. With over 1,500 employees in various roles and sectors, GSK produces vaccines and medicines that help improve the health and well-being of people around the world.

GSK’s operations in Singapore are diverse and include a state-of-the-art vaccine facility in Tuas, which is the largest vaccine production site in Singapore. The facility has been expanded with an investment of over $850 million, including the transfer of GSK’s next-generation process for hepatitis B vaccines. This investment has boosted Singapore’s biopharmaceutical innovation and helped establish the country as a global hub for sustainability leadership and innovation.

At GSK Singapore, talent and sustainability are at the forefront of our operations. We are committed to investing in our employees and providing them with opportunities to grow and develop their skills. We also recognise the importance of sustainability and are dedicated to reducing our environmental impact while continuing to provide high-quality products and services to our customers.